SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today ...

(RTTNews) - INOVIO (INO) announced promising interim results from an ongoing Phase 1 proof-of-concept ... trial is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and ...

SolasCure, a Cambridge biotech developing a novel treatment to transform chronic wound healing, has initiated a new Phase II ...

today announced the enrollment of the last patient in its NOTOXIS Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for the prevention of Cisplatin-Induced Ototoxicity (CIO). The NOTOXIS ...

Now in its third year, the trial is led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the University of Pennsylvania. It is funded by the Coronavirus ...

QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

Oragenics (OGEN) announced the submission of its Investigator’s Brochure application in preparation for its Phase II clinical trial using ...

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity ...

Inc.) "This study provides the first clinical proof-of-concept that DNA-encoded monoclonal antibodies can be durably and tolerably expressed in humans," said David B. Weiner, Ph.D, Executive Vice ...